Amanda L. Murphy Appointed as Chief Financial Officer to MaxCyte
MaxCyte Appoints Amanda L. Murphy as Chief Financial Officer and Names Ron Holtz as Senior Vice President & Chief Accounting Officer
MaxCyte, Inc., a global cell-based therapies and life sciences company, announced today that Amanda L. Murphy, CFA, has joined the Company as Chief Financial Officer (CFO). Ron Holtz, who has served as MaxCyte’s CFO since 2005, will become Senior Vice President and Chief Accounting Officer (SVP & CAO).
5 Questions with Shruti Abbato, EVP, Business Development, CARMA Cellular Therapies at MaxCyte, Inc.
Shruti has 20 years of business development experience in the biotechnology industry. She is currently responsible for building and growing MaxCyte’s CARMA Cell Therapies business. Before MaxCyte, she worked with Celdara Medical, Millendo, Medigene, Deciphera, and Human Genome Sciences. Shruti holds an MBA from the University of Pittsburgh and a BS in Chemical Engineering and Biochemistry from the University of Maryland.
Top 10 Biotech News Stories from 2019 from the BioHealth Capital Region on biobuzz.io
For 20 Years This Company Has Helped to Shape the Field of Cell Therapy How MaxCyte Has Evolved to Become Leading Technology Provider for Cell Engineering and Leveraged Its Flow [….]
The Story of Maryland’s Cell and Gene Therapy Cluster is Shared Loud and Clear at Inaugural Bio Innovation Conference
The Story of Maryland’s Cell and Gene Therapy Cluster is Shared Loud and Clear at Inaugural Bio Innovation Conference October 8, 2019 On Monday morning in Bethesda, Maryland hundreds of [….]
MaxCyte Adds Vice President, Non-Clinical and Translational Studies, to Support Advancement of Programs from Its CARMA™ Platform
MaxCyte Adds Vice President, Non-Clinical and Translational Studies, to Support Advancement of Programs from Its CARMA™ Platform Dhana Chinnasamy, PhD, will oversee non-clinical and translational activities for MaxCyte’s autologous cell [….]
Cell Therapy to Replace All Modern Medicine? In order: Phil Vanek, PhD (GE Healthcare); Claudia Zylberberg, PhD (Akron Biotechnology); Joshua Hare, MD (Longeveron); Doug Doerfler (Maxcyte) participate in the “Realizing [….]